Clearbridge BioMedics, a Singapore-based company that develops medical devices for cancer research and diagnostics, has announced a new series B financing round totaling US$7.2 million. According to a news source, the financing, led by Vertex Venture Holdings Ltd, the wholly-owned venture capital arm of Temasek Holdings, will be used to further develop the company’s propriety ClearCell System, which consists of patent-pending CTChips— microfluidic biochips—that can detect, isolate and retrieve tumor cells from patient blood samples. The isolated tumor cells can then apparently be stained for identification and analysis.

“Having already entered the cancer research market with its ClearCell System, Clearbridge BioMedics is well-positioned to have a tremendous impact on the way healthcare professionals screen, diagnose, treat and monitor cancer patients. Our investment focus has been to invest and build global champions. We see Clearbridge BioMedics, with its leading world class technology platform, as being one of them,” said Vertex Venture Managing Director and CIO Chua Joo Hock, who will join the Clearbridge BioMedics board of directors. See, March 13, 2013.